DEBORAH BAKER: Open Payments
NPI 1467630061 · BLUFFTON, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,849 in 108 payments from 16 companies in 2025. Trend: 2023 $1,930 · 2024 $1,676 · 2025 $1,849
Food & beverage: $1,639Education: $210
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 11 | $316 |
| E.R. Squibb & Sons, L.L.C. | 22 | $288 |
| Vanda Pharmaceuticals Inc. | 14 | $156 |
| ABBVIE INC. | 9 | $151 |
| Lundbeck LLC | 9 | $146 |
| Alkermes, Inc. | 7 | $142 |
| Otsuka America Pharmaceutical, Inc. | 6 | $117 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $101 |
| Tris Pharma Inc | 6 | $100 |
| Supernus Pharmaceuticals, Inc. | 4 | $74 |
Products named: REXULTI, AUSTEDO XR, COBENFY, VRAYLAR, ARISTADA, FANAPT, CAPLYTA, Dyanavel XR.
Industry payments across IN — which companies pay providers there.
